Active Ingredients
Active ingredient records sit between product names and mechanism-level understanding. They help readers connect branded products, investigational assets, formulation strategies, combination therapies, clinical development histories, and company relationships.
This area should explain ingredient-level industry context without becoming personal medical advice. Ingredient pages can describe how a molecule or combination is positioned in the obesity treatment market, which products or programs use it, and which mechanisms, indications, companies, and regulatory milestones are connected to it.
Future records should distinguish sourced facts from changing status information, especially for clinical development, regulatory review, market authorization, formulation, delivery, and commercialization claims.
This is a starting ingredient-level map for US obesity-treatment products, not treatment guidance. Product and status details should be checked against the linked source context before reuse in clinical, regulatory, pricing, or access claims.
Ingredient records should also stay separate from manufacturer records. A molecule such as semaglutide, tirzepatide, liraglutide, or orlistat can connect several products, brands, indications, and company roles. For product-level company relationships, see weight loss drug manufacturers and commercial partners.
Semaglutide is the active ingredient in Wegovy and also anchors adjacent diabetes products such as Ozempic and Rybelsus. The full ingredient record separates brand, formulation, route, indication, and regulatory status while connecting Novo Nordisk, the STEP program, GLP-1 mechanisms, and US approval history.
Sources: Semaglutide ingredient record, current DailyMed Wegovy label
Tirzepatide is the active ingredient in Zepbound, Eli Lilly’s US obesity product, and in Mounjaro, the related diabetes product. The full ingredient record separates the two brands and labels while connecting GIP/GLP-1 receptor activity, the SURMOUNT and SURPASS programs, US regulatory history, and the shared commercial platform.
Sources: Tirzepatide ingredient record, current DailyMed Zepbound label
Liraglutide
Section titled “Liraglutide”Liraglutide is the active ingredient in Saxenda, Novo Nordisk’s earlier GLP-1 obesity product. Victoza is the related liraglutide diabetes product, which makes liraglutide useful for understanding how diabetes-origin incretin products moved into obesity treatment before semaglutide and tirzepatide became the dominant obesity-market reference points.
For manufacturer-related searches, liraglutide should be read through product-specific company records rather than as a standalone manufacturing claim. Saxenda and Victoza connect liraglutide to Novo Nordisk-associated product records, but labeler, approval-holder, physical manufacturing, and market-access roles should be checked against the dated product source being used.
Source: DailyMed Saxenda label search
Phentermine/topiramate
Section titled “Phentermine/topiramate”Phentermine/topiramate is the fixed-dose active-ingredient combination used in Qsymia. It represents an oral chronic weight-management category that differs from injectable incretin products and from gastrointestinal lipase inhibition.
Source: DailyMed Qsymia label search
Naltrexone/bupropion
Section titled “Naltrexone/bupropion”Naltrexone/bupropion is the fixed-dose active-ingredient combination used in Contrave. Ingredient-level coverage should connect it to oral chronic weight-management products while keeping product ownership and commercialization details dated and source-specific.
Source: DailyMed Contrave label search
Orlistat
Section titled “Orlistat”Orlistat is the active ingredient in prescription Xenical and nonprescription Alli. It is important for the database because it connects obesity-related products to a lipase-inhibitor mechanism and to both prescription and over-the-counter market channels.
Sources: DailyMed Xenical label search, DailyMed Alli label search